Logo image of MDAI

SPECTRAL AI INC (MDAI) Stock Fundamental Analysis

NASDAQ:MDAI - Nasdaq - US84757T1051 - Common Stock - Currency: USD

2.11  +0.01 (+0.48%)

After market: 2.1381 +0.03 (+1.33%)

Fundamental Rating

1

Overall MDAI gets a fundamental rating of 1 out of 10. We evaluated MDAI against 187 industry peers in the Health Care Equipment & Supplies industry. MDAI has a bad profitability rating. Also its financial health evaluation is rather negative. MDAI is quite expensive at the moment. It does show a decent growth rate.


Dividend Valuation Growth Profitability Health

Quickly go to:

0

1. Profitability

1.1 Basic Checks

MDAI had negative earnings in the past year.
MDAI had a negative operating cash flow in the past year.
MDAI had negative earnings in 4 of the past 5 years.
In the past 5 years MDAI always reported negative operating cash flow.
MDAI Yearly Net Income VS EBIT VS OCF VS FCFMDAI Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2020 2021 2022 2023 2024 0 10M -10M -20M

1.2 Ratios

MDAI has a Return On Assets of -43.81%. This is in the lower half of the industry: MDAI underperforms 65.78% of its industry peers.
Industry RankSector Rank
ROA -43.81%
ROE N/A
ROIC N/A
ROA(3y)-39.59%
ROA(5y)-23.92%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
MDAI Yearly ROA, ROE, ROICMDAI Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2020 2021 2022 2023 2024 0 500 1K 1.5K

1.3 Margins

The Gross Margin of MDAI (45.05%) is worse than 62.03% of its industry peers.
MDAI does not have Profit Margin and Operating Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 45.05%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
MDAI Yearly Profit, Operating, Gross MarginsMDAI Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2020 2021 2022 2023 2024 0 -50 -100

More info and screens

1

2. Health

2.1 Basic Checks

MDAI does not have a ROIC to compare to the WACC, probably because it is not profitable.
MDAI has more shares outstanding than it did 1 year ago.
MDAI has a worse debt/assets ratio than last year.
MDAI Yearly Shares OutstandingMDAI Yearly Shares OutstandingYearly Shares Outstanding 2020 2021 2022 2023 2024 10M 20M 30M
MDAI Yearly Total Debt VS Total AssetsMDAI Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2020 2021 2022 2023 2024 50M 100M 150M 200M 250M

2.2 Solvency

Based on the Altman-Z score of -0.59, we must say that MDAI is in the distress zone and has some risk of bankruptcy.
Looking at the Altman-Z score, with a value of -0.59, MDAI is in line with its industry, outperforming 41.71% of the companies in the same industry.
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF N/A
Altman-Z -0.59
ROIC/WACCN/A
WACC8.69%
MDAI Yearly LT Debt VS Equity VS FCFMDAI Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2020 2021 2022 2023 2024 0 50M 100M 150M 200M

2.3 Liquidity

MDAI has a Current Ratio of 1.46. This is a normal value and indicates that MDAI is financially healthy and should not expect problems in meeting its short term obligations.
With a Current ratio value of 1.46, MDAI is not doing good in the industry: 77.54% of the companies in the same industry are doing better.
A Quick Ratio of 1.43 indicates that MDAI should not have too much problems paying its short term obligations.
MDAI's Quick ratio of 1.43 is on the low side compared to the rest of the industry. MDAI is outperformed by 61.50% of its industry peers.
Industry RankSector Rank
Current Ratio 1.46
Quick Ratio 1.43
MDAI Yearly Current Assets VS Current LiabilitesMDAI Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2020 2021 2022 2023 2024 5M 10M 15M

More info and screens

4

3. Growth

3.1 Past

The Earnings Per Share has grown by an impressive 43.33% over the past year.
Looking at the last year, MDAI shows a very strong growth in Revenue. The Revenue has grown by 63.83%.
EPS 1Y (TTM)43.33%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-93.75%
Revenue 1Y (TTM)63.83%
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%-32.27%

3.2 Future

MDAI is expected to show quite a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 19.14% yearly.
The Revenue is expected to grow by 10.53% on average over the next years. This is quite good.
EPS Next Y83%
EPS Next 2Y18.02%
EPS Next 3Y7.11%
EPS Next 5Y19.14%
Revenue Next Year-23.54%
Revenue Next 2Y-6.16%
Revenue Next 3Y2.88%
Revenue Next 5Y10.53%

3.3 Evolution

MDAI Yearly Revenue VS EstimatesMDAI Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 50M 100M 150M 200M
MDAI Yearly EPS VS EstimatesMDAI Yearly EPS VS EstimatesYearly EPS VS Estimates 2023 2024 2025 2026 2027 2028 2029 2030 2031 0 0.5 -0.5 1 -1

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

MDAI reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for MDAI. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
MDAI Price Earnings VS Forward Price EarningsMDAI Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
MDAI Per share dataMDAI EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 0.5 -0.5 1

4.3 Compensation for Growth

PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y18.02%
EPS Next 3Y7.11%

More info and screens

0

5. Dividend

5.1 Amount

No dividends for MDAI!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

SPECTRAL AI INC

NASDAQ:MDAI (8/15/2025, 8:00:01 PM)

After market: 2.1381 +0.03 (+1.33%)

2.11

+0.01 (+0.48%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupHealth Care Equipment & Services
GICS IndustryHealth Care Equipment & Supplies
Earnings (Last)08-12 2025-08-12/amc
Earnings (Next)N/A N/A
Inst Owners10.59%
Inst Owner Change0.56%
Ins Owners30%
Ins Owner Change2.69%
Market Cap54.33M
Analysts84.44
Price Target4.83 (128.91%)
Short Float %4.74%
Short Ratio1.44
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)-26.01%
Min EPS beat(2)-234.97%
Max EPS beat(2)182.96%
EPS beat(4)2
Avg EPS beat(4)-0.46%
Min EPS beat(4)-234.97%
Max EPS beat(4)182.96%
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)2
Avg Revenue beat(2)17.12%
Min Revenue beat(2)8.99%
Max Revenue beat(2)25.25%
Revenue beat(4)4
Avg Revenue beat(4)15.07%
Min Revenue beat(4)8.99%
Max Revenue beat(4)25.25%
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)-1.1%
PT rev (3m)-7.47%
EPS NQ rev (1m)0%
EPS NQ rev (3m)45%
EPS NY rev (1m)0%
EPS NY rev (3m)74.66%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)0.32%
Revenue NY rev (1m)0%
Revenue NY rev (3m)1.27%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 1.81
P/FCF N/A
P/OCF N/A
P/B N/A
P/tB N/A
EV/EBITDA N/A
EPS(TTM)-0.69
EYN/A
EPS(NY)-0.51
Fwd EYN/A
FCF(TTM)-0.31
FCFYN/A
OCF(TTM)-0.31
OCFYN/A
SpS1.16
BVpS-0.04
TBVpS-0.04
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -43.81%
ROE N/A
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 45.05%
FCFM N/A
ROA(3y)-39.59%
ROA(5y)-23.92%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score5
Asset Turnover1.43
Health
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr N/A
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 1.46
Quick Ratio 1.43
Altman-Z -0.59
F-Score5
WACC8.69%
ROIC/WACCN/A
Cap/Depr(3y)N/A
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)43.33%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-93.75%
EPS Next Y83%
EPS Next 2Y18.02%
EPS Next 3Y7.11%
EPS Next 5Y19.14%
Revenue 1Y (TTM)63.83%
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%-32.27%
Revenue Next Year-23.54%
Revenue Next 2Y-6.16%
Revenue Next 3Y2.88%
Revenue Next 5Y10.53%
EBIT growth 1Y50.16%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year51.4%
EBIT Next 3Y46.05%
EBIT Next 5Y19.67%
FCF growth 1Y-736.46%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-736.46%
OCF growth 3YN/A
OCF growth 5YN/A